THIO Sequenced With Cemiplimab in Advanced NSCLC

计划入组 227 人 · 首次发布于 2022 年 1 月 26 日

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

计划入组 300 人 · 首次发布于 2025 年 4 月 3 日

N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes

计划入组 26 人 · 首次发布于 2014 年 2 月 19 日

6-thio-2’-deoxyguanosine

2'-Deoxyguanosine-5'-Diphosphate

C₁₀H₁₅N₅O₁₀P₂

2'-Deoxyguanosine-5'-Monophosphate

C₁₀H₁₄N₅O₇P

6'Naps

Belgium

October 6 University

Egypt

Ningbo No.6 Hospital

China

MAIA Biotechnology Secures $2.44 Million in Private Placement to Advance THIO Clinical Trials

MAIA Biotechnology and BeiGene Collaborate to Evaluate THIO in Multiple Cancers

MAIA Biotechnology Doses First U.S. Patient in Phase 2 THIO-101 Expansion of Telomere-Targeting Ateganosine in Third-Line NSCLC